FDA批准Novartis' Vanrafia减少患罕见肾病IgAN的人的蛋白质尿。 FDA approves Novartis' Vanrafia to reduce proteinuria in those with the rare kidney disease IgAN.

Novartis已经获得林业发展局对Vanrafia(阿特罗斯坦)的核准,Vanrafia(阿特罗斯坦)是第一种减少成年人蛋白质尿的药物,主要患有IgA肾病(IgAN),这是一种罕见的肾病。 Novartis has received FDA approval for Vanrafia (atrasentan), the first drug to reduce proteinuria in adults with primary IgA nephropathy (IgAN), a rare kidney disease. 这种选择性内分泌素A受体对抗剂可与其他治疗方法一起使用,表明与安慰剂相比,蛋白质尿减少了36.1%。 This selective endothelin A receptor antagonist can be used alongside other treatments, showing a 36.1% reduction in proteinuria compared to placebo. IgAN在美国影响13/百万人,在50%的持久性蛋白质尿病病例中可能导致肾衰竭。 IgAN, affecting 13 per million in the US, can lead to kidney failure in up to 50% of cases with persistent proteinuria.